Last reviewed · How we verify
Formoterol powder 12 µg/unit dose
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow.
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).
At a glance
| Generic name | Formoterol powder 12 µg/unit dose |
|---|---|
| Also known as | Foradil™ |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. As a long-acting formulation, it provides extended therapeutic effect (12+ hours) compared to short-acting beta-agonists, making it suitable for maintenance therapy in chronic obstructive airway diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (maintenance therapy)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
- Tachycardia
Key clinical trials
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma (PHASE3)
- Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10) (NA)
- A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients. (PHASE2)
- A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma (PHASE3)
- Efficacy of Indacaterol 150 µg Versus Formoterol (PHASE4)
- Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer) (PHASE2)
- Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formoterol powder 12 µg/unit dose CI brief — competitive landscape report
- Formoterol powder 12 µg/unit dose updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI